Rocuronium: Difference between revisions
| (12 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
''See [[critical care quick reference]] for drug doses by weight.'' | |||
==General== | ==General== | ||
*Type: Neuromuscular blocker, Non-Depolarizing, Fast Onset, Intermediate Lasting | *Type: [[Neuromuscular blocker]], Non-Depolarizing, Fast Onset, Intermediate Lasting | ||
*Dosage Forms: IV | *Dosage Forms: IV | ||
*Common Trade Names: Zemuron | *Common Trade Names: Zemuron | ||
==Adult Dosing== | ==Adult Dosing== | ||
RSI | ===[[RSI]]=== | ||
*0.6 to 1.2mg/kg IV (actual body weight) | |||
===Maintenance Bolus Dosing=== | |||
*0.1 to 0.2mg/kg IV | |||
===Infusion=== | |||
*10 to 12 mcg/kg/min | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
RSI | ''See [[critical care quick reference]] for drug doses by weight.'' | ||
===[[RSI]]=== | |||
*0.6 to 1.2mg/kg IV (actual body weight) | |||
===Maintenance Bolus Dosing=== | |||
*0.1 to 0.2mg/kg IV | |||
===Infusion=== | |||
*10 to 12 mcg/kg/min | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
| Line 23: | Line 37: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
Anaphylaxis | *[[Anaphylaxis]] | ||
===Common=== | ===Common=== | ||
Cardiovascular: | *Cardiovascular: [[hypertension]] (0.1% to 2%) | ||
Dermatologic: Pain at injection site | *[[Hypotension]] (0.1% to 2%) | ||
Respiratory: Increased pulmonary vascular resistance (24%) | *[[Tachycardia]] (1% to 5.3%) | ||
*Dermatologic: Pain at injection site | |||
*Respiratory: Increased pulmonary vascular resistance (24%) | |||
==Pharmacology== | ==Pharmacology== | ||
| Line 34: | Line 50: | ||
*Metabolism: Metabolite is 17-desacetyl-rocuronium | *Metabolism: Metabolite is 17-desacetyl-rocuronium | ||
*Excretion: Primary route is fecal. Renal also. | *Excretion: Primary route is fecal. Renal also. | ||
*Mechanism of Action: Non-depolarizing neuromuscular blocking agent. Intermediate duration with dose dependant rapid to intermediate onset. Competes for cholinergic receptors at the motor end-plate. Acetylcholinesterase inhibitors like those found in organophosphates antagonize this action | *Mechanism of Action: Non-depolarizing neuromuscular blocking agent. Intermediate duration with dose dependant rapid to intermediate onset. Competes for cholinergic receptors at the motor end-plate. [[Acetylcholinesterase inhibitors]] like those found in organophosphates antagonize this action | ||
==See Also== | ==See Also== | ||
*[[Critical care quick reference]] | |||
*Reversal agent: [[Sugammadex]] | |||
== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | |||
[[Category: | |||
Revision as of 03:21, 5 January 2017
See critical care quick reference for drug doses by weight.
General
- Type: Neuromuscular blocker, Non-Depolarizing, Fast Onset, Intermediate Lasting
- Dosage Forms: IV
- Common Trade Names: Zemuron
Adult Dosing
RSI
- 0.6 to 1.2mg/kg IV (actual body weight)
Maintenance Bolus Dosing
- 0.1 to 0.2mg/kg IV
Infusion
- 10 to 12 mcg/kg/min
Pediatric Dosing
See critical care quick reference for drug doses by weight.
RSI
- 0.6 to 1.2mg/kg IV (actual body weight)
Maintenance Bolus Dosing
- 0.1 to 0.2mg/kg IV
Infusion
- 10 to 12 mcg/kg/min
Special Populations
- Pregnancy Rating: C
- Lactation: Infant risk cannot be ruled out
- Renal Dosing (half life approximately 1 hour longer if renal transplant patient)
- Adult
- Pediatric
- Hepatic Dosing (half life approximately 3 hours longer with liver dysfunction)
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- Cardiovascular: hypertension (0.1% to 2%)
- Hypotension (0.1% to 2%)
- Tachycardia (1% to 5.3%)
- Dermatologic: Pain at injection site
- Respiratory: Increased pulmonary vascular resistance (24%)
Pharmacology
- Half-life: Variable by age, but anywhere from 30 minutes to 2 hours.
- Metabolism: Metabolite is 17-desacetyl-rocuronium
- Excretion: Primary route is fecal. Renal also.
- Mechanism of Action: Non-depolarizing neuromuscular blocking agent. Intermediate duration with dose dependant rapid to intermediate onset. Competes for cholinergic receptors at the motor end-plate. Acetylcholinesterase inhibitors like those found in organophosphates antagonize this action
See Also
- Critical care quick reference
- Reversal agent: Sugammadex